Health News Releases

  • Today January 31
January 04, 10:40
New Prospective Study Evaluates the Accuracy of Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring During Elective Cesarean Section
Masimo (NASDAQ: MASI) today announced the findings of a prospective study published in the Egyptian Journal of Anesthesia in which Dr. Mohamed Ibrahim Beleta and colleagues at Cairo University evaluat
December 30, 2022 13:35
Biocytogen Launches RenNano™ Mouse, a Fully Human Heavy Chain Antibody Platform to Accelerate Nanobody Drug Discovery
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today officially launched its fully human heavy chain antibody platform, RenNano™. RenNano™ is the third member of the RenMic
December 23, 2022 09:25
Merck Announces Collaboration with Mersana Therapeutics to Develop Novel Immunostimulatory Antibody-Drug Conjugates
Merck, a leading science and technology company, today announced a research collaboration and commercial license agreement with Mersana Therapeutics, Inc., Cambridge, Massachusetts, USA to discover no
December 21, 2022 09:45
Boehringer Ingelheim announces appointments to Board of Managing Directors
Boehringer Ingelheim today announces that the Shareholders have appointed Paola Casarosa and Shashank Deshpande to the Board of Managing Directors. They will succeed Michel Pairet, responsible for the
December 20, 2022 10:05
Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophrenia
Boehringer Ingelheim and Click Therapeutics today announced the launch of an expanded collaboration for the development and commercialization of a second prescription-based digital therapeutic (PDT).
December 19, 2022 11:35
Biocytogen Announces FDA Clearance of IND Application for Bispecific Antibody YH008
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315) today announced that the US FDA has approved the Investigational New Drug (IND) application for a phase I study of YH008, an
December 16, 2022 16:00
CAS Introducing Transformational Capabilities to Accelerate Life Sciences Innovation
CAS, a division of the American Chemical Society specializing in scientific information solutions, announced several initiatives to once again transform scientific research, and empower more rapid dis
December 16, 2022 11:25
Artilysin®: Fearless Into the Post-antibiotic Era
The WHO has declared antibiotic resistances one of the Top 10 global threats to mankind. To counter this threat, Lysando AG has developed the so-called Artilysin® technology: Novel antimicrobial prote
December 14, 2022 16:45
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
Takeda (TSE:4502/NYSE:TAK) today announced that it will acquire NDI-034858 from Nimbus Therapeutics. NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for
December 14, 2022 15:40
Cancellation of remaining publicly held registered shares of Vifor Pharma AG
Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG (“Vifor”) announced today that the Commercial Court St. Gallen has cancelled (kraftlos erklärt) all remaining publicly
December 14, 2022 14:25
European Commission approves SPEVIGO® (spesolimab) for generalized pustular psoriasis flares
The European Commission (EC) granted a conditional marketing authorization for Boehringer Ingelheim’s spesolimab as first in class treatment for GPP flares in adults.[1] Spesolimab is a novel, selecti
December 14, 2022 10:00
AOP Health presents latest updates on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the American Society of Hematology (ASH) 2022 Annual Meeting
AOP Health announced its latest updates on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from AOP Health´s CONTINUATION-PV study (Reference Kiladjian et al. ASH 2022) and the LOW-PV
December 13, 2022 17:14
MRM Health and IFF Reach Second Milestone in the Partnered Type 2 Diabetes Program
MRM Health—a clinical-stage biopharmaceutical company focused on developing next-generation live microbiome consortia therapeutics—today announced that its Type-2 Diabetes Program, developed in collab
December 13, 2022 14:00
Masimo Announces Limited Market Release of Sepsis Index
Masimo (NASDAQ: MASI) today announced the limited market release of Sepsis Index (Si™), an early warning indicator designed to help clinicians identify possible sepsis in patients remotely monitored w
December 13, 2022 11:30
Organon Appoints Kirke Weaver as General Counsel and Corporate Secretary
Organon (NYSE: OGN), a global women’s healthcare company, today announced that Kirke Weaver has been appointed General Counsel and Corporate Secretary, and will continue as a member of Organon’s execu
December 13, 2022 10:52
GI CELL Enters Agreement with Optieum Biotechnologies
GI CELL, Inc. announced that it has entered into a research license and option agreement with Optieum Biotechnologies, Inc. (Japan). Under the agreement, Optieum Biotechnologies will provide GI CE
December 12, 2022 15:15
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
Takeda (TSE:4502/NYSE:TAK) today announced that it will present 15 company-sponsored abstracts at the 64th American Society of Hematology (ASH) Annual Meeting being held December 10-13, 2022 in New Or
December 12, 2022 10:00
Takeda’s QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) granted marketing authorization for the company’s dengue vaccine QDENGA® (Dengue Tetravalent Vaccine [Live, Attenuated]) (T
December 09, 2022 14:32
ImmuneOncia Announces Phase 2 Results of PD-L1 Immune Checkpoint Inhibitor
ImmuneOncia (CEO Heung Tae Kim) announced the results of its Phase 2 NK/T-cell lymphoma clinical trial of IMC-001, a PD-L1 monoclonal antibody, at the Asian Congress of the European Society for Medica
Eric Y. Kim, Principal Machine Learning Engineer of Bertis Bioscience
December 09, 2022 10:37
Bertis Reveals Research Results of AI-based Diagnosis Model with Proteomic Mass Spectrometry Data
Bertis, a proteomics-based precision medicine technology development company (CEOs Dong-young Noh, Seung-man Han), announced research results of AI-based disease diagnosis model, on December 8, 2022,
Ajoy Karna, CFO, Covetrus
December 09, 2022 09:30
Covetrus Names Ajoy Karna as Chief Financial Officer
Covetrus®, a global leader in animal-health technology and services, today announced the appointment of Ajoy Karna as executive vice president and chief financial officer. Karna succeeds Matthew Fouls
Michael Prosser, Chief Business Officer, Crown Bioscience
December 09, 2022 09:15
Crown Bioscience and ERS Genomics Announce Global CRISPR/Cas9 Licensing Agreement for Genome Editing Patents
Crown Bioscience, Inc, a JSR Life Sciences Company, and ERS Genomics Limited (‘ERS’) have signed a global license agreement for access to the foundational CRISPR/Cas9 patent portfolio held by ERS, whi
December 09, 2022 09:00
PDC*line Pharma Presents First Immunological Results From Phase I/II Trial With PDC*lung01 at ESMO-IO 2022
PDC*line Pharma, a clinical stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the first immunological results of its PDC-LUNG-101
December 08, 2022 10:20
Medidata Launches New myMedidata Native App to Expedite Study Start Up and Improve Patient Experience
Medidata, a Dassault Systèmes company, launched a new patient-centric native myMedidata app, designed to provide trial participants with another option for a seamless platform experience and a single
December 08, 2022 09:40
Phase III trial demonstrated Jardiance is the first SGLT2 inhibitor to show statistically significant reduction in blood sugar levels in children and adolescents with type 2 diabetes
The DINAMO Phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c (a marker of average blood sugar) with empagliflozin compared with placebo
25 per page50 per page75 per page100 per page